| Literature DB >> 28646744 |
Jacek Niklinski1, Adam Kretowski2, Marcin Moniuszko3, Joanna Reszec4, Anna Michalska-Falkowska5, Magdalena Niemira2, Michal Ciborowski2, Radoslaw Charkiewicz5, Dorota Jurgilewicz6, Miroslaw Kozlowski7, Rodryg Ramlau8, Cezary Piwkowski9, Miroslaw Kwasniewski10, Monika Kaczmarek11, Andrzej Ciereszko11, Tomasz Wasniewski12, Robert Mroz13, Wojciech Naumnik14, Ewa Sierko15, Magdalena Paczkowska2, Joanna Kisluk5, Anetta Sulewska5, Adam Cybulski7, Zenon Mariak16, Boguslaw Kedra17, Jacek Szamatowicz18, Paweł Kurzawa19, Lukasz Minarowski20, Angelika Edyta Charkiewicz21, Barbara Mroczko22, Jolanta Malyszko23, Christian Manegold24, Lothar Pilz24, Heike Allgayer25, Mohammed L Abba26, Hartmut Juhl27, Frauke Koch27.
Abstract
Personalized and precision medicine is gaining recognition due to the limitations by standard diagnosis and treatment; many areas of medicine, from cancer to psychiatry, are moving towards tailored and individualized treatment for patients based on their clinical characteristics and genetic signatures as well as novel imaging techniques. Advances in whole genome sequencing have led to identification of genes involved in a variety of diseases. Moreover, biomarkers indicating severity of disease or susceptibility to treatment are increasingly being characterized. The continued identification of new genes and biomarkers specific to disease subtypes and individual patients is essential and inevitable for translation into personalized medicine, in estimating both, disease risk and response to therapy. Taking into consideration the mostly unsolved necessity of tailored therapy in oncology the innovative project MOBIT (molecular biomarkers for individualized therapy) was designed. The aims of the project are: (i) establishing integrative management of precise tumor diagnosis and therapy including systematic biobanking, novel imaging techniques, and advanced molecular analysis by collecting comprehensive tumor tissues, liquid biopsies (whole blood, serum, plasma), and urine specimens (supernatant; sediment) as well as (ii) developing personalized lung cancer diagnostics based on tumor heterogeneity and integrated genomics, transcriptomics, metabolomics, and radiomics PET/MRI analysis. It will consist of 5 work packages. In this paper the rationale of the Polish MOBIT project as well as its design is presented. (iii) The project is to draw interest in and to invite national and international, private and public, preclinical and clinical initiatives to establish individualized and precise procedures for integrating novel targeted therapies and advanced imaging techniques.Entities:
Keywords: Biobanking; Lung Cancer; Omics; Personalized medicine; Radiomics
Mesh:
Substances:
Year: 2017 PMID: 28646744 DOI: 10.1016/j.advms.2017.05.002
Source DB: PubMed Journal: Adv Med Sci ISSN: 1896-1126 Impact factor: 3.287